Grifols (GRFS) Net Cash Flow (QoQ) (2010 - 2020)
Grifols (GRFS) Net Cash Flow (QoQ) (2010 - 2020) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 59.92% |
| Mar 31, 2019 | -141.23% |
| Jun 30, 2018 | -312.72% |
| Mar 31, 2018 | -94.87% |
| Jun 30, 2017 | -93.50% |
| Mar 31, 2017 | 5,379.98% |
| Dec 31, 2016 | 88.08% |
| Dec 31, 2015 | -577.30% |
| Sep 30, 2015 | -81.08% |
| Jun 30, 2015 | 410.58% |
| Mar 31, 2015 | 75.48% |
| Dec 31, 2014 | -132.36% |
| Sep 30, 2014 | 209.98% |
| Jun 30, 2014 | -254.33% |
| Mar 31, 2014 | 580.95% |
| Dec 31, 2013 | 164.48% |
| Sep 30, 2013 | -14.82% |
| Jun 30, 2013 | 344.55% |
| Mar 31, 2013 | -83.86% |
| Dec 31, 2012 | 42.43% |